← All countries · Americas
90%
MCV1
2025 · WHO/UNICEF estimate
86%
DTP3
2025 · WHO/UNICEF estimate
86%
IPV complete
2025 · WHO/UNICEF estimate
86%
HepB3
2025 · WHO/UNICEF estimate
38
Measles cases
2025 reported
2,746
Pertussis (whooping cough) cases
2025 reported
Two kinds of number live on this page. Coverage is the share of the target cohort vaccinated, as estimated by WHO and UNICEF each July from the country's reports, surveys and other evidence, shown beside what the country itself reported. Reported cases are what the national surveillance system sent to WHO; they are a floor, not a count of infections. Every row carries a grade; hover or focus it for the reason, or read how grades are assigned.
Vaccination coverage
| Vaccine | Latest estimate | Country-reported | Trend since 2000 | Data quality |
|---|---|---|---|---|
| BCGTuberculosis vaccine at birth | 97%2025 · WHO/UNICEF estimate | 96.6% | A · strong | |
| DTP1First dose of diphtheria-tetanus-pertussis | 98%2025 · WHO/UNICEF estimate | 97.9% | A · strong | |
| DTP3Third dose of diphtheria-tetanus-pertussis (the WHO benchmark of a working programme) | 86%2025 · WHO/UNICEF estimate | 86.4% | A · strong | |
| IPV1First dose of inactivated polio vaccine | 98%2025 · WHO/UNICEF estimate | 97.6% | A · strong | |
| IPV completeInactivated polio vaccine, complete primary series | 86%2025 · WHO/UNICEF estimate | 86.0% | C · weak | |
| MCV1First dose of measles-containing vaccine | 90%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| MCV2Second dose of measles-containing vaccine | 76%2025 · WHO/UNICEF estimate | 76.2% | A · strong | |
| RCV1First dose of rubella-containing vaccine | 90%2025 · WHO/UNICEF estimate | 90.5% | A · strong | |
| HepB3Third dose of hepatitis B vaccine | 86%2025 · WHO/UNICEF estimate | 86.4% | A · strong | |
| HepB birthHepatitis B birth dose within 24 hours | 82%2025 · WHO/UNICEF estimate | 69.5% | A · strong | |
| Hib3Third dose of Haemophilus influenzae type b vaccine | 86%2025 · WHO/UNICEF estimate | 86.4% | A · strong | |
| PCV1Pneumococcal conjugate vaccine, first dose | 96.8%2025 · Administrative (country-reported) | 96.8% | D · poor | |
| PCV completePneumococcal conjugate vaccine, final dose of the schedule | 88%2025 · WHO/UNICEF estimate | 87.7% | A · strong | |
| RotaCRotavirus vaccine, complete series | 88%2025 · WHO/UNICEF estimate | 88.4% | A · strong | |
| Yellow feverYellow fever vaccine (countries at risk) | 72%2025 · WHO/UNICEF estimate | 72.1% | A · strong | |
| MenAMeningococcal A conjugate (meningitis belt) | 88%2019 · Administrative (country-reported) | 88% | D · poor | |
| JEJapanese encephalitis vaccine (countries at risk) | —% · Administrative (country-reported) | — | too few points | no data |
| TCVTyphoid conjugate vaccine | —% · Administrative (country-reported) | — | too few points | no data |
| PABProtection at birth against neonatal tetanus (maternal tetanus doses) | 94%2024 · WHO/UNICEF estimate | — | D · poor | |
| HPV dose 1, girlsHPV programme coverage, first dose, girls | 86%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV complete, girlsHPV programme coverage, complete series, girls | 86%2025 · WHO/UNICEF estimate | — | B · good | |
| HPV dose 1, boysHPV programme coverage, first dose, boys | 74%2025 · WHO/UNICEF estimate | — | C · weak |
Reported vaccine-preventable disease
| Disease | Reported cases | Incidence rate | Trend since 2000 | Data quality |
|---|---|---|---|---|
| Measles all countries · vaccine evidence | 382025 | 0.2per 1,000,000 total population | B · good | |
| Rubella all countries · vaccine evidence | 02025 | 0per 1,000,000 total population | C · weak | |
| Congenital rubella syndrome all countries · vaccine evidence | 02025 | 0per 10,000 live births | C · weak | |
| Mumps all countries · vaccine evidence | 4,3362025 | 20.4per 1,000,000 total population | B · good | |
| Pertussis (whooping cough) all countries · vaccine evidence | 2,7462025 | 12.9per 1,000,000 total population | A · strong | |
| Diphtheria all countries · vaccine evidence | 42025 | 0per 1,000,000 total population | A · strong | |
| Tetanus (total) all countries · vaccine evidence | 2162025 | 1per 1,000,000 total population | B · good | |
| Neonatal tetanus all countries · vaccine evidence | 02025 | 0per 1,000 live births | A · strong | |
| Polio (paralytic) all countries · vaccine evidence | 02025 | 0per 1,000,000 <15 population | B · good | |
| Yellow fever all countries · vaccine evidence | 1202025 | 0.6per 1,000,000 total population | B · good | |
| Japanese encephalitis all countries · vaccine evidence | 02007 | 0per 1,000,000 total population | too few points | no data |
| Invasive meningococcal disease all countries · vaccine evidence | 1,0652025 | 5per 1,000,000 total population | C · weak | |
| Typhoid all countries · vaccine evidence | 232025 | 0.1per 1,000,000 total population | C · weak |
National schedule (latest WHO listing)
Show the schedule (74 rows)
| Vaccine | Dose | Age | Target group | Comment |
|---|---|---|---|---|
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | <Y5 | General/routine | Crianças menores de 5 anos de idade e contatos de portadores de hanseníase |
| BCGBCG (Baccille Calmette Guérin) vaccine | 1 | Risk group(s) | Crianças menores de 5 anos de idade e contatos de portadores de hanseníase | |
| COVID19COVID-19 vaccine | 1 | Adults | All older adults | |
| COVID19COVID-19 vaccine | 1 | General/routine | All children and adolescents | |
| COVID19COVID-19 vaccine | 1 | Health workers | Health and care workers | |
| COVID19COVID-19 vaccine | 1 | Pregnant women | Pregnant women | |
| COVID19COVID-19 vaccine | 1 | Risk group(s) | Children and adolescents with chronic conditions, adults with chronic conditions, older adults with chronic conditions, other groups | |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 1 | M2 | Risk group(s) | for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis) |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 2 | M4 | Risk group(s) | for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis) |
| DTDT (Tetanus toxoid and diphtheria, children's dose) vaccine | 3 | M6 | Risk group(s) | for individuals who presented post-vaccine adverse events to the pertussis component (encephalitis) |
| DTAPDTaP (acellular) vaccine | 1 | M2 | Risk group(s) | after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression |
| DTAPDTaP (acellular) vaccine | 2 | M4 | Risk group(s) | after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression |
| DTAPDTaP (acellular) vaccine | 3 | M6 | Risk group(s) | after following serious adverse vaccine events, children who are at increased risk of serious adverse vaccine events, situations of immunodepression |
| DTWPDTwP (Whole cell) vaccine | 4 | M15 | General/routine | |
| DTWPDTwP (Whole cell) vaccine | 5 | Y4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 1 | M2 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 2 | M4 | General/routine | |
| DTWPHIBHEPBDTwP-Hib-HepB (Whole cell) vaccine | 3 | M6 | General/routine | |
| HEPA_ADULTAdult Hepatitis A (HepA) vaccine | 1 | Y19 | Risk group(s) | special population; only in reference centers for special immunobiologicals |
| HEPA_PEDIATRICPediatric Hepatitis A (HepA) vaccine | 1 | M15 | General/routine | from 15 months to 4 years; 11 months and 29 days prior vaccination history |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y7 | Adults | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 1 | >=Y7 | General/routine | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | >=Y7 | Adults | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 2 | +M2 | General/routine | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | >=Y7 | Adults | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_ADULTAdult Hepatitis B (HepB) vaccine | 3 | +M2 | General/routine | =Y0>=Y7. Dose ao nascer até 30 dias e esquema de 3 doses até 60 anos e mais. |
| HEPB_PEDIATRICPediatric Hepatitis B (HepB) vaccine | 1 | B | General/routine | A recomendação é até 24h, preferencialmente nas primeiras 12h. Esta dose deve ser administrada até 30 dias de vida. As demais para completar o esquema vacinal será aplicada com penta. |
| HIBHib (Haemophilus influenzae type B) vaccine | 1 | Y19 | Risk group(s) | special population; only in reference centers for special immunobiologicals |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y14 | HPV administered to females and males | females 9-14 years; males 11-14 years; and men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 1 | Y9-Y26 | Risk group(s) | men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 2 | +M2 | Risk group(s) | men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months) |
| HPV4HPV-4 (Human papillomavirus 4-valent) vaccine | 3 | +M6 | Risk group(s) | men and women 9-26 years of special risk groups receive three doses (1st contact, +2 months, +6 months) |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | >Y18 | Adults | and older persons 60 anos ou mais |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Health workers | Health and care workers | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Pregnant women | Pregnant women | |
| INFLUENZA_ADULTAdult seasonal influenza vaccine | 1 | Risk group(s) | Adults with chronic conditions, residents living in long-term care facilities, other groups | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | >=M6 | General/routine | |
| INFLUENZA_PEDIATRICPediatric seasonal influenza vaccine | 1 | M6-Y6 | Risk group(s) | Children with chronic conditions |
| IPVIPV (Inactivated polio vaccine) | 1 | M2 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 2 | M4 | General/routine | |
| IPVIPV (Inactivated polio vaccine) | 3 | M6 | General/routine | |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 1 | M2 | Risk group(s) | patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab |
| MEN_ACYW_135CONJMeningococcal ACYW conjugate vaccine | 2 | M6-M9 | Risk group(s) | patients with nocturnal paroxysmal hemoglobinuria (PNH) who will start treatment with eculizumab |
| MEN_C_CONJMeningococcal C conjugate vaccine | 1 | M3 | General/routine | |
| MEN_C_CONJMeningococcal C conjugate vaccine | 2 | M5 | General/routine | |
| MEN_C_CONJMeningococcal C conjugate vaccine | 3 | M12 | General/routine | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | Adults | offered to people up to 49 years | |
| MMRMMR (Measles, mumps and rubella) vaccine | 1 | M12 | General/routine | |
| MMRVMMRV (Measles, mumps, rubella and varicella) vaccine | 2 | M15 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 1 | M2 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 2 | M4 | General/routine | |
| PCV10PCV-10 (Pneumococcal conjugate vaccine 10-valent) vaccine | 3 | M12 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 1 | M2 | General/routine | |
| ROTAVIRUS_1RV-1 (Rotavirus 1-valent) vaccine | 2 | M4 | General/routine | |
| RSVRSV (Respiratory syncytial virus) vaccine | 1 | Pregnant women | ||
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Health workers | Health and care workers; Pregnant adults and adolescents; Immunocompromised persons | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Pregnant women | Health and care workers; Pregnant adults and adolescents; Immunocompromised persons | |
| TDAP_STdap (Tetanus, diphtheria for older children and adults and acellular pertussis) vaccine | 1 | Risk group(s) | Health and care workers; Pregnant adults and adolescents; Immunocompromised persons | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y7 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 1 | >=Y7 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | >=Y7 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 2 | +M2 | General/routine | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | >=Y7 | Adults | |
| TD_STd (Tetanus toxoid and diphtheria for older children and adults) vaccine | 3 | +M6 | General/routine | |
| VARICELLAVaricella vaccine | 1 | Y4 | General/routine | |
| VARICELLAVaricella vaccine | 1 | Health workers | Unvaccinated health professionals | |
| VITAMINAVitamin A supplements | 1 | M6-M11 | General/routine | |
| VITAMINAVitamin A supplements | 2 | M12-M18 | General/routine | |
| VITAMINAVitamin A supplements | 3 | M19-M25 | General/routine | |
| VITAMINAVitamin A supplements | 4 | M26-M32 | General/routine | |
| VITAMINAVitamin A supplements | 5 | M33-M39 | General/routine | |
| VITAMINAVitamin A supplements | 6 | M40-M46 | General/routine | |
| YFYF (Yellow fever) vaccine | 1 | M9 | General/routine | |
| YFYF (Yellow fever) vaccine | 2 | Y4-Y60 | General/routine |
Compare schedules across 31 countries on the schedule hub.
Data and sources
- Download this country's data (JSON): every year, every antigen and disease, with the grade reasons.
- Coverage: WHO/UNICEF Estimates of National Immunization Coverage (WUENIC) and country-reported administrative/official coverage, from the WHO Immunization Data Portal export downloaded 21 October 2026.
- Reported cases and incidence: WHO/UNICEF Joint Reporting Form, same export. Incidence denominators are stated per row.
- Schedule: WHO vaccine-schedule export, latest listing year.